In the past week, IMUX stock has gone down by -12.63%, with a monthly decline of -20.88% and a quarterly plunge of -34.47%. The volatility ratio for the week is 3.68%, and the volatility levels for the last 30 days are 7.79% for Immunic Inc The simple moving average for the past 20 days is -6.65% for IMUX’s stock, with a -33.89% simple moving average for the past 200 days.
Is It Worth Investing in Immunic Inc (NASDAQ: IMUX) Right Now?
IMUX has 36-month beta value of 1.49. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMUX is 92.56M, and currently, short sellers hold a 4.59% ratio of that float. The average trading volume of IMUX on June 18, 2025 was 1.39M shares.
IMUX) stock’s latest price update
Immunic Inc (NASDAQ: IMUX)’s stock price has decreased by -0.96 compared to its previous closing price of 0.77. However, the company has seen a -12.63% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-09 that Immunic, Inc.’s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock’s significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results.
Analysts’ Opinion of IMUX
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IMUX reach a price target of $10. The rating they have provided for IMUX stocks is “Buy” according to the report published on November 25th, 2024.
Leerink Partners gave a rating of “Outperform” to IMUX, setting the target price at $5 in the report published on September 09th of the previous year.
IMUX Trading at -18.82% from the 50-Day Moving Average
After a stumble in the market that brought IMUX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.98% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMUX starting from Nash Duane, who purchase 20,000 shares at the price of $0.83 back on Jun 13 ’25. After this action, Nash Duane now owns 36,032 shares of Immunic Inc, valued at $16,694 using the latest closing price.
Tardio Jason, the President and COO of Immunic Inc, purchase 12,512 shares at $0.79 during a trade that took place back on Jun 05 ’25, which means that Tardio Jason is holding 12,512 shares at $9,884 based on the most recent closing price.
Stock Fundamentals for IMUX
The total capital return value is set at 19.89. Equity return is now at value -246.26, with -154.64 for asset returns.
Based on Immunic Inc (IMUX), the company’s capital structure generated -0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -393.2.
Currently, EBITDA for the company is -100.37 million with net debt to EBITDA at 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
To put it simply, Immunic Inc (IMUX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
